GlassScriptPhysician profile
Maram A Yousef
NPI 1093161010
$946.20
in general payments reported to CMS, 2019-2025
12 companies · $759 in 2025
The $759 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.43 · 2022: $25.00 · 2024: $123 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $188.54 | 2024-2025 | |
| Axsome Therapeutics, INC. | $147.27 | 2025 | Auvelity |
| Corium, LLC | $137.92 | 2024-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $136.44 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.51 | 2025 | Caplyta |
| Indivior INC. | $61.39 | 2024-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $45.79 | 2024-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $42.03 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.43 | 2021 | |
| Avanir Pharmaceuticals, INC. | $25.00 | 2022 | |
| Neuronetics, INC. | $15.09 | 2025 | Neurostar Tms Therapy System |
| E.R. Squibb & Sons, L.L.C. | $14.79 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maram Yousef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.